Marc Hilmi (@MarcHilmi) header
Marc Hilmi (@MarcHilmi) profile picture
MSKCC, Manhattan, NY, USA
Joined September 2021
Photo by Marc Hilmi (@MarcHilmi)Photo by Marc Hilmi (@MarcHilmi)Photo by Marc Hilmi (@MarcHilmi)Photo by Marc Hilmi (@MarcHilmi)Photo by Marc Hilmi (@MarcHilmi)Photo by Marc Hilmi (@MarcHilmi)Photo by Marc Hilmi (@MarcHilmi)Photo by Marc Hilmi (@MarcHilmi)Photo by Marc Hilmi (@MarcHilmi)Photo by Marc Hilmi (@MarcHilmi)
After almost 1 year @MSKCancerCenter @CpcrMsk ๐Ÿš€ Honored to present at #AACRpan25 uncovering mechanisms of resistance & response on the POLAR trial. Exciting 2nd year ahead! @CentralParkWMD @EileenMOReilly @ciacobu @jmsongmd @CatherineaOC @MichaelMayMD #PancreaticCancer
3
1
22
3,248
๐Ÿ”ฅ PRIME-HCC - The Lancet Oncology ๐Ÿ’Š Nivolumab ร—2 cycles + ipilimumab once, before resection of early-stage HCC ๐Ÿ‘ฅ 33 patients, Phase 1b, safety primary endpoint โœ… 30 of 33 (91%) reached surgery; grade 3 trAEs 9%, no grade 4โ€“5 ๐Ÿ“Š ORR 25%, disease control 97% ๐Ÿฉธ ctDNA-negative after surgery: 2-year RFS 82% vs 29% โš ๏ธ Single arm, 18 patients in the ctDNA comparison Most of our patients with resectable HCC go straight to surgery and then wait to see whether it comes back, which happens far too often. - PRIME-HCC shows dual checkpoint blockade before resection is safe enough: 91% reached the operating room and grade 3 toxicity was 9%. This is the main finding of a phase 1 trial. - A 25% response rate in 33 pts is not efficacy, and the authors say so. - The part I find most useful is ctDNA: clearance after surgery split 2-year RFS 82% vs 29%, though on 18 evaluable patients. That is a hypothesis for selecting who needs adjuvant therapy, not yet a test to act on. #HCC #LiverCancer #Immunotherapy #ctDNA #GIOnc thelancet.com/journals/lanonโ€ฆ
3
6
415
Marc Hilmi retweeted
AmCORE Study: Age-Related Outcomes in Colorectal Liver Metastases A retrospective AmCORE-based study evaluated treatment patterns and survival outcomes in 351 patients with colorectal liver metastases (CRLM) across three age groups: <50, 50โ€“69, and โ‰ฅ70 years. Key findings: โ–ซ๏ธ Induction systemic therapy: 58.1% of patients aged <50 years received treatment, compared with 40.5% and 21.8% in the older age groups (P < 0.001). โ–ซ๏ธ Disease burden: Younger patients had more liver metastases at diagnosis (median 4 vs 2 vs 2; P = 0.030). โ–ซ๏ธ PFS: Differed significantly across age groups, with shorter PFS in patients aged <50 years (P = 0.019). โ–ซ๏ธ OS: No significant difference across age groups (P = 0.22), despite differences in treatment intensity. Takeaway: Younger patients received more intensive systemic therapy but experienced shorter PFS, while OS remained comparable across age groups. Greater disease burden at diagnosis may partly explain these findings, supporting individualized treatment decisions based on disease characteristics rather than age alone. @rj_swijnenburg @TBuffart oncodaily.com/gastrointestinโ€ฆ #AmCORE #ColorectalCancer #GIOncology
6
8
250
๐Ÿ“Š Onvansertib - FDA Fast Track ๐ŸŽฏ First-line KRAS- or NRAS-mutated metastatic CRC ๐Ÿ’Š Onvansertib (PLK1 inhibitor) + FOLFIRI/bevacizumab ๐Ÿ”€ Randomised Phase 2 CRDF-004 trial โœ… Confirmed ORR 72.2% vs 42.1% with FOLFIRI/bev alone โฑ๏ธ Median PFS not reached vs about 11 months, company-reported and immature โš ๏ธ A designation, not an approval Most patients with RAS-mut mCRC, whether left- or right-sided, who have no actionable target receive first-line chemo + bevacizumab. A 30%-point ORR gain in a randomized phase 2 trial is a real signal, and Fast Track designation should facilitate discussions with the FDA. But a designation is not an approval, ORR is not survival, and the PFS comparison is company-reported and still immature. The question I want answered in phase 3 is whether those extra responses translate into more time for patients or enable more of them to undergo liver resection.. Btw: Open at Moffitt (for 1L mCRC KRAS-mut): โ€ข ROSETTA CRC-203: Pumitamig + Chemo vs Bevacizumab + Chemo in 1L Metastatic CRC (MMRp/MSS, BRAF WT) - NCT07221357 โ€ข ERAS-0015 (Pan-RAS Molecular Glue) ยฑ Pembrolizumab or Panitumumab in RAS-Mutant Advanced Solid Tumors (AURORAS-1) - NCT06983743 โ€ข VS-7375 (Oral KRAS G12D ON/OFF Inhibitor) ยฑ Anti-EGFR Antibody in KRAS G12D-Mutated Metastatic CRC (TARGET-D 203) - NCT07659795 - - - [email protected] - - trials.allanpereira.com #CRC #mCRC #KRAS #GIOnc globenewswire.com/news-releaโ€ฆ
6
13
951
The European Commission has approved daraxonrasib (RASONQUEยฎ), the first broad RAS-targeted therapy for metastatic pancreatic cancer An important milestone for patients with pancreatic adenocarcinoma ๐Ÿ’œ A promising step forward! #PancreaticCancer @RevMedicines
3
23
78
3,728
Marc Hilmi retweeted
Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR CRC: pls 2 UNICORN trial @NatureMedicine ๐Ÿ‘‰pMR rate: 0% in pMMR BOT 36% in pMMR BOT + BAL 36% in dMMR BOT 100% in dMMR BOT + BAL ๐Ÿงinteresting efficacy for BOT + BAL in early pMMR or dMMR CC @myESMO @ASCO
14
27
2,024
Look at these curves - ๐Ÿ”ฅ NICHE-2 at five years - Phase 2 (The Lancet) ๐ŸŽฏ Stage IIโ€“III dMMR colon cancer, before surgery ๐Ÿ’Š Ipilimumab ร—1 + nivolumab ร—2, then resection ๐Ÿ‘ฅ 111 per-protocol patients, six Dutch hospitals โœ… 3-year DFS 100% at a median 58.7 mo โœ… 5-year OS 100% (exploratory) ๐Ÿฉธ ctDNA cleared in 80/97 before surgery, all negative after โš ๏ธ Single-arm, no comparator The pathological response rates from NICHE-2 were already striking; this is the survival follow-up that tells us they held. Zero recurrences across 111 patients, after only roughly a month of treatment w/o chemo before surgery. The comparison that now matters is with *ATOMIC*, which added atezolizumab to adjuvant FOLFOX after surgery: two routes to curing dMMR colon cancer, one of them with six months of chemotherapy and one without. NICHE-2 is single-arm, so one can say that a randomized comparison is still owed before it replaces surgery-first. #CRC #dMMR thelancet.com/journals/lanceโ€ฆ
1
10
15
979
5/6 Cancer vaccines could eventually move into prevention or interception: "In theory, a vaccine against 25 recurrent mutational hotspots in genes such as KRAS, BRAF, and PIK3CA could target mutations found in more than 70% of colorectal, pancreatic, uterine, and melanoma..."
2
2
7
405
๐Ÿง โšก Where great minds meet and ideas sPARK! Incredible few days at @CSHL at Banbury with @lustgartenfdn! A small room filled with epic minds who shaped the last 20 years and brilliant new minds shaping the next 5โ€“10 years of #PancreaticCancer research. Bert Vogelstein @ldiaz1971 Liz Jaffee Nilo Azad @DavidHongMD Jenifer Knox Erica Tsang Harshabad Singh Brian Wolpin Andy Aguirre David Tuveson Dan Nussenbaum @DrDanielKing Vincent Bernard and more~~ From #KRAS biology and resistance to new therapeutic strategies, to interception, the science was deep and the discussions even deeper! Came to learn from the legends and left thinking differently myself. ๐Ÿš€๐Ÿ’œ The best science doesnโ€™t just answer questions. It changes how we think. #PDAC #RAS #TeamScience @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk
1
3
28
1,218
From POLAR to AURORA, Dr. Wungki Park (@CentralParkWMD) from @MSKCancerCenter explores the connections between DNA repair and tumor immunity. #BRCASymposium
2
5
198
Marc Hilmi retweeted
โญ Eileen Oโ€™Reilly, MD, of @MSKCancerCenter reviews findings from the AMPLIFY-7P trial evaluating #camupepimut in resected KRAS-mutated #PDAC. ๐Ÿ“บ Watch Dr. Oโ€™Reilly discuss the link between immune activation and clinical benefit: buff.ly/NQvyGkd
1
7
20
1,252
Via @NatPancFdn, a webinar tomorrow, 11 Nov 2026, 6PM Eastern. Advances in genetic testing, precision medicine, targeted therapies, immunotherapy, vaccines, & other approaches. Register here: zoom.us/webinar/register/WN_โ€ฆ
2
4
235
Marc Hilmi retweeted
Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications @Cancer_Cell doi.org/10.1016/j.ccell.2026โ€ฆ ๐Ÿ‘Interesting perspective ๐Ÿ‘‰Detrimental effect on PFS & OS ๐Ÿ‘‰Time to consider gut microbiome ๐ŸงWe need strategies to mitigate antibiotic-induced dysbiosis and preserve ICI responses @myESMO @ASCO
1
19
44
2,875
Marc Hilmi retweeted
๐Ÿฅ @nyulangone Perlmutter Cancer Center has appointed @VivekSubbiah, MD, Director of Early-Phase Drug Development and Rare Cancer Programs. ๐Ÿฉบ He brings 15+ years of experience in #PrecisionOncology and clinical research. Learn more โžก๏ธ ascopost.com/news/november-2โ€ฆ
2
17
2
79
12,542
Congratulations @FASinicropeMD @ALLIANCE_org - Alliance GI committee- highlighting the importance of federally funded practice changing NCI studies - ATOMIC - new adjuvant standard in MSI-H/dMMR colon @NEJM @NCCN @FDA nice to see highlighted in plenary session!
2
8
553
Second player in this space - excited for most recent update for zoci (DLL3 ADC) phase 1b/2 program: 40% RR, mDOR 5.6 mo in chemorefractory pts, activity seen in DLL3-low/negative pts as well. Frontline cohort now open, phase 3 designs being discussed. #NANETS2026
1
6
17
887
โœจ Excited to share new work in @NatureGenet, with next-door neighbor @SohrabShah! Our labs โ€“ led by @nceglia; @GreedyApple; Zach Sethna; and @elhanati_yuval - applied information theory and probabilistic modeling to the question of how T cell dynamics changes in response to immunotherapy, particularly coupling between a T cell's T cell receptor (TCR) and its phenotypic state. T cell responses are critical to cancer immunotherapies. Their behavior is often strongly influenced by their TCR, which directly engages with antigens presented on the cell surface. How clonal the sequenced TCR repertoire is in a dataset has been used to understand response โ€“ TCRs that recognize an antigen multiply โ€“ but its often a noisy measure, and we wanted to extend this logic to single-cell data in an eqiposed way. Information theory offers a solution. The specific question of how information is propagated between the TCR and its phenotypic state also becomes a general way to probe genotype-phenotype mapping. The mutual information between receptor and state - that is how much knowing about one tells you information about the other - and how that changes can then be used to probe therapeutic response. Given data sparsity this becomes a problem in probabilistic inference โ€“ which was addressed here via a cool hierarchical Bayesian framework led by @GreedyApple & @nceglia. A flux in phenotype and stronger mutual information post-treatment was associated with response to immunotherapy. In non-responders, therapy did not improve poor communication between TCR and phenotype. Hence information dynamics can be used to measure response. We are already collectively using this approach across many, many projects. We use variants to analyze vaccine data with @TheVinodLab at the Olayan Center for Cancer Vaccines @MSKCancerCenter, in multiple projects with @break_cancer, throughout the Halvorsen Center @CompOncMSK, and elsewhere. It was a lot of fun and we hope you enjoy! Code link included! ๐Ÿ‘‡ ๐Ÿ‘‡ ๐Ÿ‘‡ nature.com/articles/s41588-0โ€ฆ
2
25
1
96
5,821